Patents by Inventor Sung Youl HONG

Sung Youl HONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody binding specifically to ECL-2 of claudin 3, fragment thereof, and use thereof
    Patent number: 12098198
    Abstract: The invention of the present application relates to a use of an antibody binding specifically to ECL-2 of claudin 3 and functional fragments thereof in cancer cell detection, diagnosis, imaging, and application to cancer treatment (anticancer use of the antibody itself, and application to ADC and CAR-expression cells (particularly immune cells)), an antibody that includes a characteristic CDR sequence exerting a remarkable effect in such uses, and a functional fragment thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 24, 2024
    Assignee: ABION INC.
    Inventors: Young Kee Shin, Sung Youl Hong, Young Deug Kim, Jun Young Choi, Heo Bin Yang, Ha Yeon Park, Sung Su Kim
  • COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA
    Publication number: 20230241176
    Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-threonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine.
    Type: Application
    Filed: August 29, 2022
    Publication date: August 3, 2023
    Inventors: Young Kee SHIN, Tae Eun KIM, Sung Youl HONG, Jun Young CHOI, Na Young KIM
  • Composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA
    Patent number: 11464832
    Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine, and to a composition for sensitizing interferon beta resistant cancer cells comprising cFLIP siRNA as an active ingredient.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 11, 2022
    Assignees: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, ABION INC.
    Inventors: Young Kee Shin, Tae Eun Kim, Sung Youl Hong, Jun Young Choi, Na Young Kim
  • COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA
    Publication number: 20210299225
    Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine, and to a composition for sensitizing interferon beta resistant cancer cells comprising cFLIP siRNA as an active ingredient.
    Type: Application
    Filed: July 31, 2017
    Publication date: September 30, 2021
    Inventors: Young Kee SHIN, Tae Eun KIM, Sung Youl HONG, Kyoung SONG, Hun Soon JUNG, Joo Seok KIM, Sang Yun LEE
  • ANTIBODY BINDING SPECIFICALLY TO ECL-2 OF CLAUDIN 3, FRAGMENT THEREOF, AND USE THEREOF
    Publication number: 20210115134
    Abstract: The invention of the present application relates to a use of an antibody biding specifically to ECL-2 of claudin 3 and functional fragments thereof in cancer cell detection, diagnosis, imaging, and application to cancer treatment (anticancer use of the antibody itself, and application to ADC and CAR-expression cells (particularly immune cells)), an antibody that includes a characteristic CDR sequence exerting a remarkable effect in such uses, and a functional fragment thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: April 22, 2021
    Inventors: Young Kee SHIN, Sung Youl HONG, Young Deug KIM, Jun Young CHOI, Heo Bin YANG, Ha Yeon PARK, Sung Su KIM